Showing results (151-160 of 253) with videos related to

Sort By:
Pageof 26
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 18, 2009
Split-skin grafting from the scalp: the hidden advantageGerhard H Weyandt, Boris Bauer, Nikolaus Berens, et al.
The Journal of Investigative Dermatology|October 19, 2016
Allergy-Inducing Chromium Compounds Trigger Potent Innate Immune Stimulation Via ROS-Dependent Inflammasome ActivationChristian Adam, Jonas Wohlfarth, Maike Haußmann, et al.
JMIR Mhealth and Uhealth|May 29, 2026
Patient-Centered Lupus Erythematosus Mobile Apps: Systematic Search and Cross-Sectional Evaluation by Patients and PhysiciansTassilo Dege, Antonia Ullmann, Caroline Glatzel, et al.
Plos One|January 30, 2014
p53 regulation by TRP2 is not pervasive in melanomaRoland Houben, Corinna P Schmid, Melissa Maier, et al.
The Journal of Biological Chemistry|June 17, 2010
Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4)Nils Ohnesorge, Dorothee Viemann, Nicole Schmidt, et al.
Deutsches Arzteblatt International|October 30, 2016
The Risk of Bacterial Infection After TattooingRalf Dieckmann, Ides Boone, Stefan O Brockmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 26, 2024
Practical recommendations for therapy and monitoring of mogamulizumab patients in GermanyChalid Assaf, Nina Booken, Edgar Dippel, et al.
Contact Dermatitis|June 15, 2019
Improved metal allergen reactivity of artificial skin models by integration of Toll-like receptor 4-positive cellsVerena G Frings, Damaris Müller, Gabriel Storz, et al.
Molecular and Cellular Biology|January 17, 2003
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturationMartin Leverkus, Martin R Sprick, Tina Wachter, et al.
Melanoma Research|May 22, 2018
Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitorsAlexander Thiem, Patrick Schummer, Simon Ueberschaar, et al.
Pageof 26